생물학적 제제 시장

Biologics Market - Scope of Report

TMR's report on the global Biologics Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the Market during the forecast period from 2025 to 2035. The report provides revenue of the global Biologics Market for the period 2025 to 2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Biologics Market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Biologics Market .

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Biologics Market .

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Biologics Market. These serve as valuable tools for existing Market players as well as for entities interested in participating in the global Biologics Market .

The report delves into the competitive landscape of the global Biologics Market. Key players operating in the global Biologics Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Biologics Market profiled in this report.

Key Questions Answered in Global Biologics Market Report:

• What are the opportunities in the global Biologics Market ?
• What are the major drivers, restraints, opportunities, and threats in the Market ?
• Which regional Market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2035?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the Market positions of different companies operating in the global Market ?

Biologics Market - Research Objectives and Research Approach

The comprehensive report on the global Biologics Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the Market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the Market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Biologics Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the Market share for each of these at the end of 2035 has been provided. Such valuable insights enable Market stakeholders in making informed business decisions for investment in the global Biologics Market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Biologics Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Biologics Market Analysis and Forecast, 2020 to 2035
  • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

• 5.1. Key Industry Events
• 5.2. Porter's Five Forces Analysis
• 5.3. PESTEL Analysis
• 5.4. Disease Prevalence & Incidence Rate
• 5.5. Pipeline Analysis
• 5.6. Regulatory Scenario by Key Countries/Regions
• 5.7. Reimbursement Scenario by Key Countries/Regions
• 5.8. Pricing Trends
• 5.9. Treatment Algorithm & Options
• 5.10. End-user Preference

6. Global Biologics Market Analysis and Forecast, by Product Type

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Product Type, 2020 to 2035
  • 6.3.1. Monoclonal Antibodies
  • 6.3.2. Recombinant Proteins
  • 6.3.3. Vaccines
  • 6.3.4. Cell & Gene Therapy Products
  • 6.3.5. Others
• 6.4. Market Attractiveness Analysis, by Product Type

7. Global Biologics Market Analysis and Forecast, by Indication

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Indication, 2020 to 2035
  • 7.3.1. Oncology
  • 7.3.2. Autoimmune & Immunological Disorders
  • 7.3.3. Hematological Disorders
  • 7.3.4. Infectious Diseases
  • 7.3.5. Others
• 7.4. Market Attractiveness Analysis, by Indication

8. Global Biologics Market Analysis and Forecast, by Manufacturing

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Manufacturing, 2020 to 2035
  • 8.3.1. Outsourced
  • 8.3.2. In-house
• 8.4. Market Attractiveness Analysis, by Manufacturing

9. Global Biologics Market Analysis and Forecast, by Distribution Channel

• 9.1. Introduction & Definition
• 9.2. Key Findings/Developments
• 9.3. Market Value Forecast, by Distribution Channel, 2020 to 2035
  • 9.3.1. Retail Pharmacies
  • 9.3.2. Hospital Pharmacies
  • 9.3.3. Online Pharmacies
• 9.4. Market Attractiveness Analysis, by Distribution Channel

10. Global Biologics Market Analysis and Forecast, by Region

• 10.1. Key Findings
• 10.2. Market Value Forecast, by Region, 2020 to 2035
  • 10.2.1. North America
  • 10.2.2. Europe
  • 10.2.3. Asia Pacific
  • 10.2.4. Latin America
  • 10.2.5. Middle East & Africa
• 10.3. Market Attractiveness By Region

11. North America Biologics Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Product Type, 2020 to 2035
  • 11.2.1. Monoclonal Antibodies
  • 11.2.2. Recombinant Proteins
  • 11.2.3. Vaccines
  • 11.2.4. Cell & Gene Therapy Products
  • 11.2.5. Others
• 11.3. Market Value Forecast, by Indication, 2020 to 2035
  • 11.3.1. Oncology
  • 11.3.2. Autoimmune & Immunological Disorders
  • 11.3.3. Hematological Disorders
  • 11.3.4. Infectious Diseases
  • 11.3.5. Others
• 11.4. Market Value Forecast, by Manufacturing, 2020 to 2035
  • 11.4.1. Outsourced
  • 11.4.2. In-house
• 11.5. Market Value Forecast, by Distribution Channel, 2020 to 2035
  • 11.5.1. Retail Pharmacies
  • 11.5.2. Hospital Pharmacies
  • 11.5.3. Online Pharmacies
• 11.6. Market Value Forecast, by Country, 2020 to 2035
  • 11.6.1. U.S.
  • 11.6.2. Canada
• 11.7. Market Attractiveness Analysis
  • 11.7.1. By Product Type
  • 11.7.2. By Indication
  • 11.7.3. By Manufacturing
  • 11.7.4. By Distribution Channel
  • 11.7.5. By Country

12. Europe Biologics Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Product Type, 2020 to 2035
  • 12.2.1. Monoclonal Antibodies
  • 12.2.2. Recombinant Proteins
  • 12.2.3. Vaccines
  • 12.2.4. Cell & Gene Therapy Products
  • 12.2.5. Others
• 12.3. Market Value Forecast, by Indication, 2020 to 2035
  • 12.3.1. Oncology
  • 12.3.2. Autoimmune & Immunological Disorders
  • 12.3.3. Hematological Disorders
  • 12.3.4. Infectious Diseases
  • 12.3.5. Others
• 12.4. Market Value Forecast, by Manufacturing, 2020 to 2035
  • 12.4.1. Outsourced
  • 12.4.2. In-house
• 12.5. Market Value Forecast, by Distribution Channel, 2020 to 2035
  • 12.5.1. Retail Pharmacies
  • 12.5.2. Hospital Pharmacies
  • 12.5.3. Online Pharmacies
• 12.6. Market Value Forecast, by Country/Sub-region, 2020 to 2035
  • 12.6.1. Germany
  • 12.6.2. U.K.
  • 12.6.3. France
  • 12.6.4. Italy
  • 12.6.5. Spain
  • 12.6.6. Switzerland
  • 12.6.7. The Netherlands
  • 12.6.8. Rest of Europe
• 12.7. Market Attractiveness Analysis
  • 12.7.1. By Product Type
  • 12.7.2. By Indication
  • 12.7.3. By Manufacturing
  • 12.7.4. By Distribution Channel
  • 12.7.5. By Country/Sub-region

13. Asia Pacific Biologics Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Product Type, 2020 to 2035
  • 13.2.1. Monoclonal Antibodies
  • 13.2.2. Recombinant Proteins
  • 13.2.3. Vaccines
  • 13.2.4. Cell & Gene Therapy Products
  • 13.2.5. Others
• 13.3. Market Value Forecast, by Indication, 2020 to 2035
  • 13.3.1. Oncology
  • 13.3.2. Autoimmune & Immunological Disorders
  • 13.3.3. Hematological Disorders
  • 13.3.4. Infectious Diseases
  • 13.3.5. Others
• 13.4. Market Value Forecast, by Manufacturing, 2020 to 2035
  • 13.4.1. Outsourced
  • 13.4.2. In-house
• 13.5. Market Value Forecast, by Distribution Channel, 2020 to 2035
  • 13.5.1. Retail Pharmacies
  • 13.5.2. Hospital Pharmacies
  • 13.5.3. Online Pharmacies
• 13.6. Market Value Forecast, by Country/Sub-region, 2020 to 2035
  • 13.6.1. China
  • 13.6.2. India
  • 13.6.3. Japan
  • 13.6.4. South Korea
  • 13.6.5. Australia & New Zealand
  • 13.6.6. Rest of Asia Pacific
• 13.7. Market Attractiveness Analysis
  • 13.7.1. By Product Type
  • 13.7.2. By Indication
  • 13.7.3. By Manufacturing
  • 13.7.4. By Distribution Channel
  • 13.7.5. By Country/Sub-region

14. Latin America Biologics Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Product Type, 2020 to 2035
  • 14.2.1. Monoclonal Antibodies
  • 14.2.2. Recombinant Proteins
  • 14.2.3. Vaccines
  • 14.2.4. Cell & Gene Therapy Products
  • 14.2.5. Others
• 14.3. Market Value Forecast, by Indication, 2020 to 2035
  • 14.3.1. Oncology
  • 14.3.2. Autoimmune & Immunological Disorders
  • 14.3.3. Hematological Disorders
  • 14.3.4. Infectious Diseases
  • 14.3.5. Others
• 14.4. Market Value Forecast, by Manufacturing, 2020 to 2035
  • 14.4.1. Outsourced
  • 14.4.2. In-house
• 14.5. Market Value Forecast, by Distribution Channel, 2020 to 2035
  • 14.5.1. Retail Pharmacies
  • 14.5.2. Hospital Pharmacies
  • 14.5.3. Online Pharmacies
• 14.6. Market Value Forecast, by Country/Sub-region, 2020 to 2035
  • 14.6.1. Brazil
  • 14.6.2. Mexico
  • 14.6.3. Argentina
  • 14.6.4. Rest of Latin America
• 14.7. Market Attractiveness Analysis
  • 14.7.1. By Product Type
  • 14.7.2. By Indication
  • 14.7.3. By Manufacturing
  • 14.7.4. By Distribution Channel
  • 14.7.5. By Country/Sub-region

15. Middle East & Africa Biologics Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast, by Product Type, 2020 to 2035
  • 15.2.1. Monoclonal Antibodies
  • 15.2.2. Recombinant Proteins
  • 15.2.3. Vaccines
  • 15.2.4. Cell & Gene Therapy Products
  • 15.2.5. Others
• 15.3. Market Value Forecast, by Indication, 2020 to 2035
  • 15.3.1. Oncology
  • 15.3.2. Autoimmune & Immunological Disorders
  • 15.3.3. Hematological Disorders
  • 15.3.4. Infectious Diseases
  • 15.3.5. Others
• 15.4. Market Value Forecast, by Manufacturing, 2020 to 2035
  • 15.4.1. Outsourced
  • 15.4.2. In-house
• 15.5. Market Value Forecast, by Distribution Channel, 2020 to 2035
  • 15.5.1. Retail Pharmacies
  • 15.5.2. Hospital Pharmacies
  • 15.5.3. Online Pharmacies
• 15.6. Market Value Forecast, by Country/Sub-region, 2020 to 2035
  • 15.6.1. GCC Countries
  • 15.6.2. South Africa
  • 15.6.3. Rest of Middle East & Africa
• 15.7. Market Attractiveness Analysis
  • 15.7.1. By Product Type
  • 15.7.2. By Indication
  • 15.7.3. By Manufacturing
  • 15.7.4. By Distribution Channel
  • 15.7.5. By Country/Sub-region

16. Competition Landscape

• 16.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 16.2. Market Share Analysis, by Company (2024)
• 16.3. Company Profiles
  • 16.3.1. AbbVie, Inc.
    • 16.3.1.1. Company Overview
    • 16.3.1.2. Financial Overview
    • 16.3.1.3. Product Portfolio
    • 16.3.1.4. Business Strategies
    • 16.3.1.5. Recent Developments
  • 16.3.2. Amgen
    • 16.3.2.1. Company Overview
    • 16.3.2.2. Financial Overview
    • 16.3.2.3. Product Portfolio
    • 16.3.2.4. Business Strategies
    • 16.3.2.5. Recent Developments
  • 16.3.3. AstraZeneca plc
    • 16.3.3.1. Company Overview
    • 16.3.3.2. Financial Overview
    • 16.3.3.3. Product Portfolio
    • 16.3.3.4. Business Strategies
    • 16.3.3.5. Recent Developments
  • 16.3.4. Bristol-Myers Squibb Company
    • 16.3.4.1. Company Overview
    • 16.3.4.2. Financial Overview
    • 16.3.4.3. Product Portfolio
    • 16.3.4.4. Business Strategies
    • 16.3.4.5. Recent Developments
  • 16.3.5. Eli Lilly & Company
    • 16.3.5.1. Company Overview
    • 16.3.5.2. Financial Overview
    • 16.3.5.3. Product Portfolio
    • 16.3.5.4. Business Strategies
    • 16.3.5.5. Recent Developments
  • 16.3.6. Gilead Sciences, Inc.
    • 16.3.6.1. Company Overview
    • 16.3.6.2. Financial Overview
    • 16.3.6.3. Product Portfolio
    • 16.3.6.4. Business Strategies
    • 16.3.6.5. Recent Developments
  • 16.3.7. GSK plc
    • 16.3.7.1. Company Overview
    • 16.3.7.2. Financial Overview
    • 16.3.7.3. Product Portfolio
    • 16.3.7.4. Business Strategies
    • 16.3.7.5. Recent Developments
  • 16.3.8. Johnson & Johnson Services, Inc.
    • 16.3.8.1. Company Overview
    • 16.3.8.2. Financial Overview
    • 16.3.8.3. Product Portfolio
    • 16.3.8.4. Business Strategies
    • 16.3.8.5. Recent Developments
  • 16.3.9. Merck & Co., Inc.
    • 16.3.9.1. Company Overview
    • 16.3.9.2. Financial Overview
    • 16.3.9.3. Product Portfolio
    • 16.3.9.4. Business Strategies
    • 16.3.9.5. Recent Developments
  • 16.3.10. Novartis AG
    • 16.3.10.1. Company Overview
    • 16.3.10.2. Financial Overview
    • 16.3.10.3. Product Portfolio
    • 16.3.10.4. Business Strategies
    • 16.3.10.5. Recent Developments
  • 16.3.11. Pfizer, Inc.
    • 16.3.11.1. Company Overview
    • 16.3.11.2. Financial Overview
    • 16.3.11.3. Product Portfolio
    • 16.3.11.4. Business Strategies
    • 16.3.11.5. Recent Developments
  • 16.3.12. F. Hoffmann-La Roche AG
    • 16.3.12.1. Company Overview
    • 16.3.12.2. Financial Overview
    • 16.3.12.3. Product Portfolio
    • 16.3.12.4. Business Strategies
    • 16.3.12.5. Recent Developments
  • 16.3.13. Regeneron Pharmaceuticals Inc.
    • 16.3.13.1. Company Overview
    • 16.3.13.2. Financial Overview
    • 16.3.13.3. Product Portfolio
    • 16.3.13.4. Business Strategies
    • 16.3.13.5. Recent Developments